Potential of Tahongai leaf extracts (Kleinhovia Hospital.) in handling vaginal discharge caused candida albicans: laboratory study

Abstract

Background

Candida Albicans is the main causative pathogenic microorganism with a recurrence rate of 40-45% causing disruption of the female reproductive organs and conventional discomfort and treatment causing various side effects and resistance. For this reason, it is necessary to conduct research to prove herbal ingredients as a potential alternative treatment in cases of pathological vaginal discharge that are expected to contribute to midwifery services.

Objective

To aim the potential of effective extracts of tahongai leaves able to inhibit candida albicans in vitro, as well as the duration of the inhibitory power of more than 24 hours.

Method

True experimental post-test only control group design, subjects used candida albicans isolates from vaginal patients with the Mc Farland standard suspension 0.5. The inhibitory test uses the disk diffusion method using Fluconazole control.

Results

There are influences of inhibition of various concentrations namely 0.39%, 0.78%, 1.56%, 3.125%, 6.25%, 12.5%, 25%, 50%, 75%, 100% of candida albicans with ANOVA statistical tests (p_value<0.05 ) The post-hoc test results showed that the concentration of effective extract was 100% with Fluconazole having a inhibition power not different or the same as the p value = 0.999 (> 0.05) because the average strength of the delay was not far adrift. The old ability of extract inhibition also exceeds 24 hours, which is 48 hours with 72 hours indicating the same inhibition power than before. So, the future opportunity to use tahongai leaf extract clinically can be used once a day for vaginal discharge.

Conclusions and Recommendations

The effective 100% concentration of tahongai leaf extract has the potential as an alternative ingredient for vaginal discharge caused by albicans candida. next study preclinical test Potential of tahongai leaf extract Tahongai leaf extract (Kleinhoviahospita L.) to the inhibition of candida albicans with experimental animal subjects. So that the results of research can be applied to humans as an alternative treatment for vaginal discharge in providing midwifery care to reproductive health services for women of childbearing age.